| dbo:abstract |
Cel-Sci Corporation (NYSE American: CVM), is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products. Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration (FDA). The therapeutic has also been referred to as Leukocyte Interleukin Injection (LI). Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. 928 patients were enrolled in the head and neck cancer drug trial at that time. In June 2021, the company announced that the study missed its primary endpoint. (en) |
| dbo:foundingYear |
1983-01-01 (xsd:gYear) |
| dbo:industry |
dbr:Biotechnology |
| dbo:locationCity |
dbr:Vienna,_Virginia |
| dbo:netIncome |
-2.2E7 (dbd:usDollar) |
| dbo:operatingIncome |
-2.0E7 (dbd:usDollar) |
| dbo:revenue |
559000.0 (dbd:usDollar) |
| dbo:revenueYear |
2020-01-01 (xsd:gYear) |
| dbo:type |
dbr:Public_company |
| dbo:wikiPageExternalLink |
https://cel-sci.com/ |
| dbo:wikiPageID |
63280117 (xsd:integer) |
| dbo:wikiPageLength |
12121 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1096958313 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Rheumatoid_arthritis dbr:Vaccine dbr:Vienna,_Virginia dbr:Public_company dbr:Orphan_drug dbr:Germany dbr:NYSE_American dbr:The_New_York_Times dbr:The_Washington_Post dbr:U.S._Securities_and_Exchange_Commission dbr:Head_and_neck_cancer dbr:Dutch_people dbr:FDA dbr:Food_and_Drug_Administration dbc:Biotechnology_companies_established_in_1983 dbr:HIV/AIDS dbr:Argentina dbc:Life_sciences_industry dbc:Orphan_drug_companies dbr:Biotechnology dbr:Switzerland dbr:Syneos_Health dbr:Autoimmunity dbr:Immunotherapy dbr:Neoadjuvant_therapy dbr:Squamous_cell_carcinoma |
| dbp:founded |
1983 (xsd:integer) |
| dbp:founder |
Maximilian de Clara (en) |
| dbp:hqLocationCity |
dbr:Vienna,_Virginia |
| dbp:hqLocationCountry |
United States (en) |
| dbp:incomeYear |
2019 (xsd:integer) |
| dbp:industry |
Biotechnology (en) |
| dbp:keyPeople |
Geert Kersten, CEO (en) |
| dbp:name |
Cel-Sci Corporation (en) |
| dbp:netIncome |
(en) -2.2E7 (dbd:usDollar) |
| dbp:netIncomeYear |
2019 (xsd:integer) |
| dbp:operatingIncome |
(en) -2.0E7 (dbd:usDollar) |
| dbp:products |
Multikine, LEAPS, HGP-30 (en) |
| dbp:revenue |
(en) 559000.0 (dbd:usDollar) |
| dbp:revenueYear |
2020 (xsd:integer) |
| dbp:tradedAs |
AMEX:CVM (en) |
| dbp:type |
dbr:Public_company |
| dbp:website |
https://cel-sci.com/ |
| dbp:wikiPageUsesTemplate |
dbt:Advert dbt:Infobox_company dbt:Multiple_issues dbt:Orphan |
| dct:subject |
dbc:Biotechnology_companies_established_in_1983 dbc:Life_sciences_industry dbc:Orphan_drug_companies |
| rdf:type |
owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 dbo:Organisation |
| rdfs:comment |
Cel-Sci Corporation (NYSE American: CVM), is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products. (en) |
| rdfs:label |
Cel-Sci Corporation (en) |
| owl:sameAs |
wikidata:Cel-Sci Corporation https://global.dbpedia.org/id/BzuJi |
| prov:wasDerivedFrom |
wikipedia-en:Cel-Sci_Corporation?oldid=1096958313&ns=0 |
| foaf:homepage |
https://cel-sci.com/ |
| foaf:isPrimaryTopicOf |
wikipedia-en:Cel-Sci_Corporation |
| foaf:name |
Cel-Sci Corporation (en) |
| is dbo:wikiPageWikiLink of |
dbr:Nicholas_Stacey |
| is foaf:primaryTopic of |
wikipedia-en:Cel-Sci_Corporation |